Drug intelligence / Profile preview

Shenmei Pian

Development stage: Unknown
Lead developer: Beijing Shanqing Pharmaceutical Technology
Administration: Oral

Overview

Shenmei Pian is a traditional Chinese medicine (TCM) tablet developed by Beijing Shanqing Pharmaceutical Technology Co., Ltd. for the treatment of generalized anxiety disorder (GAD). It is specifically formulated to address the TCM syndrome of "heat disturbing the heart-mind," a pattern characterized by restlessness, irritability, and sleep disturbances. The drug underwent Phase 2 clinical evaluation in China (CTR20132599) to assess its efficacy and safety over a 6-week treatment period. As a botanical product, its therapeutic effect is derived from a combination of herbal ingredients intended to clear internal heat and soothe the spirit to alleviate symptoms of anxiety.

Brand names: Shenmei Pian
Other names: 参梅片

Beyond the preview

Go deeper on Shenmei Pian.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shenmei Pian.

Explore the full profile